Session: 721. Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Toxicities: Poster I
Hematology Disease Topics & Pathways:
Research, Clinical trials, Lymphoid Leukemias, ALL, Combination therapy, Lymphomas, Clinical Research, B Cell lymphoma, Diseases, Aggressive lymphoma, Treatment Considerations, Lymphoid Malignancies, Adverse Events
Patients and Methods: The eligibility criteria were age 18-70 years with CD22(+) disease requiring HCT. The other inclusion criteria were an ECOG performance status score of 0-2 and adequate liver function (serum bilirubin <2 mg/dL and liver enzyme <2 times the upper limit of normal), renal function (creatinine ≤1.6 mg/dL), cardiac function (ejection fraction ≥45%), and pulmonary function (≥50% of predictive value). In addition, patients were required to have a 6/6 HLA-compatible sibling donor or an HLA-A, HLA-B, HLA-C, and DRB1-matched unrelated donor (MUD) if no sibling donors were available. INO was infused intravenously (IV) on day -13 outpatient, at a dose of 0.3 mg/m2. Fludarabine 30 mg/m2 IV daily on days -5 to -2 and melphalan 140 mg/m2 IV on day -2 were given prior to HCT. Tacrolimus and mini-methotrexate were used for graft versus host disease (GVHD) prophylaxis. Patients who received transplants from MUDs received an additional dose of methotrexate 5 mg/m2 on day +11 and 1 mg/kg of rabbit anti-thymocyte globulin IV on days -1 and -2 before HCT.
Results: The study included 9 patients with a median age of 54 (range, 27-64) years. Disease types included B-ALL (n=7 [6 in first complete remission (CR1) and 1 in CR2]) and lymphoma (n=2; 1 with Richter’s transformation and 17p deletion), and they all expressed CD22. Risk factors for patients with ALL included the presence of TP53 mutation with complex cytogenetics in 3 patients; 1 also had KMT2A mutation, and another had primary induction failure sensitive to salvage. One additional patient had KMT2A mutation, 1 had IKZF1 mutation with persistent minimal residual disease detected by clonoSEQ, and 1 had Philadelphia-like (Ph) disease. The patient who was in CR2 at transplant had Ph+ ALL and was maintained on ponatinib after HCT. Key prior therapies in ALL patients included blinatumomab (n=5) and INO (n=5). The maximum doses of INO received prior to HCT were 1.2, 1.5, 2.7, and 2.7 mg/m2; 1 patient received an unknown dose at an outside facility. Six (67%) received their transplants from matched sibling donors and 3 (33%) from MUDs. All patients experienced engraftment after receiving unmanipulated donor grafts. Neutrophil counts recovered to more than 0.5 x 109/L a median of 12 days after HCT (range, 9-19 days). Platelet counts recovered to more than 20 x 109/L after a median of 13 days (range, 0-27 days). All patients experienced donor cell engraftment, and no secondary graft failure occurred. None of the treated patients developed veno-occlusive disease. Treatment-related mortality at 2 years was 14%. With a median follow-up of 13 months (range, 1-36 months), the 2-year overall survival and progression-free survival rates were 62% and 60%, respectively. Two patients experienced a relapse: 1 with initial primary induction failure with TP53 mutation and 1 with KMT2A mutation who had extramedullary sarcoma at relapse after HCT. The 2 other patients with TP53 mutation and complex cytogenetics remained alive at 18 and 36 months. The 2 relapsed patients died, together with the Ph-like ALL patient who died in CR due to GVHD. The incidence of grade II-IV GVHD was 48%. One patient had chronic extensive GVHD.
Conclusions: Our conclusions are limited by the small number of patients due to slow accrual. However, our data suggest that INO is safe when combined with a melphalan plus fludarabine HCT conditioning regimen. The survival outcomes are encouraging and need to be validated in a larger number of patients. Currently, post-transplant cyclophosphamide has been implemented to lessen the risk of GVHD.
Disclosures: Khouri: Pfizer: Research Funding; Bristol Myers Squibb: Research Funding. Kantarjian: AbbVie, Amgen, Ascentage, Ipsen Biopharmaceuticals, KAHR Medical, Novartis, Pfizer, Shenzhen Target Rx, Stemline,Takeda: Consultancy, Honoraria. Abbas: Enzyme By Design: Research Funding; Illumina: Honoraria, Other: Inkind Support, Research Funding; Genentech: Research Funding; GlaxoSmithKline: Research Funding; Ascentage: Research Funding; Alamar Biosciences: Honoraria; Molecular Partners: Consultancy; Blueprint Medicines Corporation: Research Funding. Sasaki: Enliven: Research Funding; Chugai: Other: Lecture fees; Pfizer: Consultancy; Daiichi-Sankyo: Consultancy; Otsuka: Other: Lecture fees; Novartis: Consultancy, Research Funding. Jain: NovalGen: Research Funding; MingSight: Honoraria, Research Funding; Servier: Research Funding; Precision Biosciences: Consultancy, Honoraria, Other: Travel Support, Research Funding; Ipsen: Consultancy, Honoraria, Other: Travel Support; Pfizer: Research Funding; Medisix: Research Funding; Fate Therapeutics: Research Funding; MEI Pharma: Consultancy, Honoraria, Other: Travel Support; Takeda: Research Funding; BeiGene: Consultancy, Honoraria, Other: Travel Support; Kite, a Gilead Company: Consultancy, Honoraria, Other: Travel Support, Research Funding; Janssen: Consultancy, Honoraria, Other: Travel Support; Bristol Myers Squibb: Consultancy, Honoraria, Other: Travel Support, Research Funding; Aprea Therapeutics: Research Funding; Newave: Research Funding; TG Therapeutics: Consultancy, Honoraria, Other: Travel Support; Dialectic Therapeutics: Research Funding; TransThera Sciences: Research Funding; Cellectis: Consultancy, Honoraria, Other: Travel Support, Research Funding; Genentech: Consultancy, Honoraria, Other: Travel Support, Research Funding; ADC Therapeutics: Research Funding; CareDx: Consultancy, Honoraria, Other: Travel Support; Loxo Oncology: Research Funding; Pharmacyclics: Consultancy, Honoraria, Other: Travel Support, Research Funding; Incyte: Research Funding; AstraZeneca: Consultancy, Honoraria, Other: Travel Support, Research Funding; Adaptive Biotechnologies: Consultancy, Honoraria, Other: Travel Support, Research Funding; AbbVie: Consultancy, Honoraria, Other: Travel Support, Research Funding. Kadia: Sellas: Consultancy, Research Funding; Cellenkos: Research Funding; Pfizer: Research Funding; Regeneron: Research Funding; DrenBio: Consultancy, Research Funding; JAZZ: Research Funding; Ascentage: Research Funding; Rigel: Honoraria; AstraZeneca: Research Funding; Genentech: Consultancy, Research Funding; Novartis: Honoraria; Abbvie: Consultancy, Research Funding; Servier: Consultancy; BMS: Consultancy, Research Funding; Amgen: Research Funding; Incyte: Research Funding; ASTEX: Research Funding. Shpall: Adaptimmune Limited: Other: Scientific Advisor; National Marrow Donor Program: Other: Board of Directors/Management; Zelluna Immunotherapy: Other: Scientific Advisor; FibroBiologics: Other: Scientific Advisor; Axio Research: Current Employment, Other: Scientific Advisor. Kebriaei: Pfizer: Consultancy, Honoraria; Jazz Pharmaceuticals: Consultancy, Honoraria. Jabbour: AbbVie, Adaptive Biotechnologies, Amgen, Astellas Pharma, BMS, Genentech, Incyte, Pfizer, Takeda: Consultancy; AbbVie, Adaptive Biotechnologies, Amgen, Ascentage Pharma Group, Pfizer, Takeda: Research Funding.
OffLabel Disclosure: The use of inotuzumab ozogamicin as part of the conditioning regimen for allogeneic stem cell transplantation.